1. Paw Cho Sing, E., et al., Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer, 2019. 66 (5): p. e27646.

2. Patel, P., et al., Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer, 2017. 64 (10).

3. Hesketh, P.J., et al., Antiemetics: ASCO Guideline Update. J Clin Oncol, 2020. 38 (24): p. 2782-2797.

4. Naik, R.D., et al., Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. J Clin Oncol, 2020. 38 (32): p. 3785-3793.

5. Patel, P., et al., Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. Pediatr Blood Cancer, 2020. 67 (12): p. e28716.

6. Bakhshi, S., et al., Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer, 2015.23 (11): p. 3229-37.

7. Kang, H.J., et al., Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol, 2015. 16 (4): p. 385-94.

8. Flank, J., et al., Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Support Care Cancer, 2018.26 (2): p. 549-555.

9. Popovic, M., et al., Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.Support Care Cancer, 2014. 22 (6): p. 1685-97.